Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe

Soleno Therapeutics (SLNO) shares fell 9.68% after Scorpion Capital released a critical short report alleging its sole product, Vykat XR, is unsafe for children with Prader-Willi syndrome—citing reported hospitalizations for potential heart failure—and is significantly overpriced at $500,000 annually. The report also raises concerns over data integrity from a key investigator and warns SLNO stock could collapse to penny-stock levels, drawing parallels to Zafgen's failure, given Soleno's reliance on a single product with an expiring patent.

Analysis

Soleno Therapeutics (SLNO) experienced a significant 9.68% stock price decline to $69.87 following the release of a damaging short report by Scorpion Capital. The report targets Soleno's sole product, Vykat XR, a recently FDA-approved treatment for Prader-Willi syndrome (PWS), alleging it is unsafe and prohibitively expensive at a purported $500,000 annual cost. Central to the report are claims of multiple children being hospitalized for potential heart failure after starting the drug, raising the specter of market withdrawal or a sharp drop in new prescriptions. This situation is explicitly compared to the 2015 collapse of PWS drug developer Zafgen, creating a powerful negative narrative. The report further undermines confidence by questioning the integrity of Soleno's clinical trial data, citing irregularities linked to a lead investigator who was also involved with Zafgen. These allegations directly challenge the viability of Soleno's business model, which is described as a 'one-trick pony' with no other significant drugs in its pipeline and a key patent set to expire in 2026. While the company has reported initial commercial traction with 646 patient start forms and $32.7 million in product revenue, these early metrics are now overshadowed by fundamental questions regarding product safety, data validity, and long-term commercial sustainability.

Key Decisions for Investors

• Investors should treat the safety allegations regarding patient hospitalizations as the primary risk factor, as any validation of these claims by the company or the FDA could be catastrophic for the stock.
• Monitor for an official company response to the short report's specific allegations, as well as any statements from regulatory bodies, which will be the next major catalysts for the stock's direction.
• Given the company's single-product dependency and the near-term patent expiration in 2026, the risk profile has increased substantially, warranting a re-evaluation of long positions.
• Potential investors should exercise extreme caution, as the report's warning of a potential fall to 'penny-stock' levels highlights a highly unfavorable risk/reward dynamic until the safety and data integrity concerns are fully resolved.